Circio Holding ASA

Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 4 July 2025: Reference is made to the stock exchange announcement by

Circio Holding ASA (OSE:CRNA) (the "Company") on 30 June 2025, regarding the

requested conversion of convertible bonds by Atlas Special Opportunities, LLC.

The share capital increase has now been registered with the Norwegian Register

of Business Enterprises (Nw. Foretaksregisteret). The Company's new share

capital is NOK 63,305,046.60 divided into 105,508,411 shares, each with a

nominal value of NOK 0.60.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683 34 3811

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic cassette design for

efficient biogenesis of multifunctional circRNA inside cells. The circVec

platform has applications in multiple therapeutic settings, including genetic

medicine, cell therapy and chronic disease. It has demonstrated over 70-fold

prolonged RNA half-life and up to 15-fold enhanced protein expression vs.

conventional mRNA vector systems in vivo, and has the potential to become a

new gold-standard protein expression technology. The circRNA R&D activities

are being conducted by the wholly owned subsidiary Circio AB in Stockholm,

Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

AI Terminal